Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
33%(1 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_2
4
100%

Phase Distribution

0

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
terminatedphase_2

Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

NCT04679350
completedphase_2

Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia

NCT04679415
completedphase_2

Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia

NCT04676971
completedphase_2

Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)

NCT01687387

Clinical Trials (4)

Showing 4 of 4 trials
NCT04679350Phase 2

Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia

Terminated
NCT04679415Phase 2

Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia

Completed
NCT04676971Phase 2

Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia

Completed
NCT01687387Phase 2

Efficacy Study of Anti-KIR Monoclonal Antibody as Maintenance Treatment in Acute Myeloid Leukemia (EFFIKIR)

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4